Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study

Oncology Reports

Volumn 18, Issue 3, 2007, Pages 665-671

  Wei, Yanzhang C ^a,c   Sticca, Robert P ^a,d   Li, Jinhua ^a   Holmes, Lillia M ^a   Burgin, Kelly E ^a   Jakubchak, Susan ^a   Bouton Verville, Hilary ^a   Williamson, Jane ^a   Meyer, Karen ^a   Evans, Lyndon ^b   Martin, Julie ^b   Stephenson, Joseph J ^b   Trocha, Steven ^a   Smith, Sam ^a   Wagner, Thomas E ^a,c  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

^b Cancer Centers of the Carolinas   (United States)

^c CLEMSON UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Dendritoma; Immunotherapy; Renal cell carcinoma

Indexed keywords

CANCER VACCINE; INTERLEUKIN 2;

AGED; ARTICLE; CANCER STAGING; DENDRITE; FEMALE; HUMAN; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; PATHOLOGY;

AGED; CANCER VACCINES; CARCINOMA, RENAL CELL; DENDRITES; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 38449120099     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.3.665     Document Type: Article

References (23)

1. Eggener SE, Yossepowitch O, Pettus JA, et al: Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24: 3101-3106, 2006. (Pubitemid 46638947)
2. Drucker BJ: Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 31: 536-545, 2005.
3. Lam JS, Belldegrun AS and Figlin RA: Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother 7: 705-720, 2006.
4. Mickisch GH and Mattes RH: Combination of surgery and immunotherapy in metastatic renal cell carcinoma. World J Urol 23: 191-195, 2005. (Pubitemid 41136041)
5. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24, 2006. (Pubitemid 46630489)
6. Gouttefangeas C, Stenzl A, Stevanovic S, et al: Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 56: 117-128, 2007. (Pubitemid 44812454)
7. Rosenblatt J, Kufe D and Avigan D: Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther 5: 703-715, 2005. (Pubitemid 40780553)
8. Den Brok MH, Nierkens S, Figdor CG, et al: Dendritic cells: tools and targets for antitumor vaccinations. Exp Rev Vaccines 4: 699-710, 2005 (Pubitemid 41530593)
9. Ribas A: Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 5: 619-628, 2005.
10. Farkas A, Conrad C, Tonel G, et al: Current state and perspectives of dendritic cells vaccination in cancer immunotherapy. Skin Pharmacol Physiol 19: 124-131, 2006.
11. Avigan D, Vasir B, Gong J, et al: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 10: 4699-4708, 2004. (Pubitemid 38955520)
12. Sheng KC, Pieterxz GA, Wright MD, et al: Dendritic cells; activation and maturation - applications for cancer immunotherapy. Curr Med Chem 12: 1783-1800, 2005. (Pubitemid 40895000)
13. Berntsen A, Geertsen PF and Svane IM: Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 50: 34-43, 2006. (Pubitemid 43850125)
14. Holmes LM, Li J, Sticca RP, et al: A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte (CTL) responses using instant dendritomas. J Immunother 24: 122-129, 2001. (Pubitemid 32183058)
15. Li J, Holmes LM, Franek KJ, Burgin KE, et al: Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 50: 456-462, 2001. (Pubitemid 33079341)
16. Wei Y, Sticca RP, Holmes LM, et al: Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 28: 585-594, 2006.
17. Spagnoli GC, Adamina M, Bolli M, et al: Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation. World J Surg 29: 692-699, 2005. (Pubitemid 41187527)
18. Lucignani G, Ottobrini L, Martelli C, et al: Molecular imaging of cell-mediated cancer immunotherapy. Trends Biotechnol 24: 410-418, 2006. (Pubitemid 44223823)
19. Wan H and Dupasquier M: Dendritic cells in vivo and in vitro. Cell Mol Immunol 2: 28-35, 2005.
20. Peng JC, Thomas R and Nielsen LK: Generation and maturation of dendritic cells for clinical application under serum-free conditions. J Immunother 28: 599-609, 2005. (Pubitemid 41533094)
21. Lindner M and Schirrmacher V: Tumor cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylene-glycol versus electro-fusion protocols. Eur J Clin Invest 32: 207-217, 2002. (Pubitemid 36216606)
22. Siders WM, Vergilis KL, Johnson C, et al: Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7: 498-505, 2003. (Pubitemid 36553419)
23. Linuma H, Okinaga K, Fukushima R, et al: Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma. J Immunol 176: 3461-3469, 2006. (Pubitemid 43363993)